White Matter Disease in Cerebral Organic Acid Disorders: Clinical Implications and Suggested Pathomechanisms

 

 Buy Article Permissions and Reprints

Abstract

White matter abnormalities (including dys-, hypo-, demyelination and delayed myelation) are frequently found in cerebral organic acid disorders, a recently delineated subgroup of inherited organic acid disorders presenting predominantly with a neurological symptomatology. Biochemically, this disease subgroup lacks metabolic derangements, such as hypoglycemia, hyperammonemia and acidosis, and is characterized by an accumulation of organic acids that share structural similarities with the excitatory amino acid glutamate (D-2-, L-2-, 3-hydroxyglutarate, glutarate) or have been suggested as neurotransmitters/neuromodulators (N-acetylaspartylglutamate). Evidence from in vitro and in vivo studies is growing that relevant organic acids significantly contribute to the neuropathology of these diseases via interference with glutamatergic or GABAergic neurotransmission or impairment of energy metabolism. This article provides an overview on the clinical and neuroradiological presentation of white matter disease in cerebral organic acid disorders, focusing on the suggested pathomechanistic relevance of excitotoxicity, oxidative stress, and impaired energy metabolism.

References

• 1 Adachi M, Aronson S M. Studies on spongy degeneration of the central nervous system (van Bogaert-Bertrand type). Aronson SM, Volk BW Inborn Disorders of Sphingolipid Metabolism. Oxford; Pergamon Press 1967: 129
  Google Scholar
• 2 Albin R L, Greenamyre J T. Alternative excitotoxic hypothesis.  Neurology. 1992;  42 733-738
  PubMedGoogle Scholar
• 3 Back S A, Gan X, Li Y, Rosenberg P A, Volpe J J. Maturation-dependent vulnerability of oligodendrocytes to oxidative stress-induced death caused by glutathione depletion.  J Neurosci. 1998;  18 6241-6253
  CrossrefPubMedGoogle Scholar
• 4 Barres B A, Raff M C, Gaese F, Bartke I, Dechant G, Barde Y A. A crucial role for neurotrophin-3 in oligodendrocyte development.  Nature. 1994;  367 371-375
  CrossrefPubMedGoogle Scholar
• 5 Barth P G, Hoffmann G F, Jaeken J, Wanders R JA, Duran M, Jansen G A. et al . L-2-Hydroxyglutaric acidaemia: clinical and biochemical findings in 12 patients and preliminary report on L-2-hydroxyacid dehydrogenase.  J Inherit Metab Dis. 1993;  16 753-761
  CrossrefPubMedGoogle Scholar
• 6 Beal M F, Brouillet E, Jenkins B G, Ferrante R J, Kowall N W, Miller J M. et al . Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid.  J Neurosci. 1993;  13 4181-4192
  PubMedGoogle Scholar
• 7 Beaudet A L. Aspartoacylase deficiency (Canavan disease). Scriver CR, Beaudet AL, Valle AD, Sly WS The Metabolic and Molecular Bases of Inherited Disease. New York; McGraw-Hill 2001: 5799-5805
  Google Scholar
• 8 Brismar J, Brismar G, Gascon G, Ozand P. Canavan disease: CT and MR imaging of the brain.  Am J Neuroradiol. 1990;  11 805-810
  PubMedGoogle Scholar
• 9 Brismar J, Ozand P T. CT and MR of the brain in glutaric acidemia type I: a review of 59 published cases and a report of 5 new patients.  Am J Neuroradiol. 1995;  16 675-683
  PubMedGoogle Scholar
• 10 Burlina A P, Ferrari V, Divry P, Gradowska W, Jakobs C, Bennett M J. et al . N-Acetylaspartylglutamate in Canavan disease: an adverse effector?.  Eur J Pediatr. 1999;  158 406-409
  CrossrefPubMedGoogle Scholar
• 11 Chew L J, Fleck M W, Wright P, Scherer S E, Mayer M L, Gallo V. Growth factor-induced transcription of GluR1 increases functional AMPA receptor density in glial progenitor cells.  J Neurosci. 1997;  17 227-240
  PubMedGoogle Scholar
• 12 Chow C W, Haan E A, Goodman S I, Anderson R M, Evans W A, Kleinschmidt-DeMasters B K. et al . Neuropathology of glutaryl-CoA dehydrogenase deficiency.  Acta Neuropathol. ;  76 590-594
  PubMedGoogle Scholar
• 13 Da Silva C G, Ribeiro C AJ, Leipnitz G, Dutra-Filho C S, Wyse A TS, Wannmacher C MD. et al . Inhibition of cytochrome c oxidase activity in rat cerebral cortex and human skeletal muscle by D-2-hydroxyglutaric acid in vitro.  Biochim Biophys Acta. 2002;  1586 81-91
  PubMedGoogle Scholar
• 14 De Mello C F, Kölker S, Ahlemeyer B, de Souza F R, Fighera M R, Mayatepek E. et al . Intrastriatal administration of 3-hydroxyglutaric acid induces convulsions and excitotoxic lesions in rats.  Brain Res. 2001;  916 70-75
  CrossrefPubMedGoogle Scholar
• 15 D'Incerti L, Farina L, Moroni I, Uziel G, Savoiardi M. L-2-Hydroxyglutaric aciduria: MRI in seven cases.  Neuroradiology. 1998;  40 727-733
  CrossrefPubMedGoogle Scholar
• 16 Dugan L L, Sensi S L, Canzoniero L M, Handran S D, Rothman S M, Lin T S. et al . Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate.  J Neurosci. 1995;  15 6377-6388
  PubMedGoogle Scholar
• 17 Follett P L, Rosenberg P A, Volpe J J, Jensen F E. NBQX attenuates excitotoxic injury in developing white matter.  J Neurosci. 2000;  20 9235-9241
  PubMedGoogle Scholar
• 18 Gallo V, Wright P W, McKinnon R D. Expression and regulation of a glutamate receptor subunit by bFGF in oligodendrocyte progenitors.  Glia. 1994;  10 149-153
  CrossrefPubMedGoogle Scholar
• 19 Gegelashvili G, Schousboe A. High affinity glutamate transporters: regulation of expression and activity.  Mol Pharmacol. 1997;  52 5-15
  PubMedGoogle Scholar
• 20 Greene J G, Porter R HP, Eller R V, Greenamyre J T. Inhibition of succinate dehydrogenase by malonic acid produces an excitotoxic lesion in rat striatum.  J Neurochem. 1993;  61 1151-1154
  PubMedGoogle Scholar
• 21 Hanefeld F, Kruse B, Bruhn H, Frahm J. In vivo proton magnetic resonance spectroscopy of the brain in a patient with L-2-hydroxyglutaric aciduria.  Pediatr Res. 1994;  35 614-616
  CrossrefPubMedGoogle Scholar
• 22 Hardy R, Reynolds R J. Neuron-oligodendroglial interactions during central nervous system development.  Neurosci Res. 1993;  36 121-126
  PubMedGoogle Scholar
• 23 Heyes M P. Hypothesis: a role for quinolinic acid in the neuropathology of glutaric aciduria type I.  Can J Neurol Sci. 1987;  14 441-443
  PubMedGoogle Scholar
• 24 Hoffmann G F, Trefz F K, Barth P, Böhles J H, Biggemann B, Bremer H J. et al . Glutaryl-CoA deficiency: a distinct encephalopathy.  Pediatrics. 1991;  88 1194-1203
  PubMedGoogle Scholar
• 25 Hoffmann G F, Gibson K M, Trefz F K, Nyhan W L, Bremer H J, Rating D. Neurological manifestations of organic acid disorders.  Eur J Ped. 1994;  153 (Suppl 1) S94-100
  PubMedGoogle Scholar
• 26 Hoffmann G F, Athanassopoulos S, Burlina A B, Duran M, deKlerck J BC, Lehnert W. et al . Clinical course, early diagnosis, treatment, and prevention of disease in glutaryl-CoA dehydrogenase deficiency.  Neuropediatrics. 1996;  27 115-123
  Article in Thieme ConnectPubMedGoogle Scholar
• 27 Jacobson M. Developmental Neurobiology. 3rd ed. New York; Plenum Press 1991: 776
  Google Scholar
• 28 Kagawa T, Wada T, Ikenaka K. Regulation of oligodendrocyte development.  Microsc Res Tech. 2001;  52 740-745
  CrossrefPubMedGoogle Scholar
• 29 Kavanaugh B, Beesley J, Itoh T, Itoh A, Grinspan J, Pleasure D. Neurotrophin-3 (NT-3) diminishes susceptibility of the oligodendroglial lineage to AMPA glutamate receptor-mediated excitotoxicity.  J Neurosci Res. 2000;  60 725-732
  CrossrefPubMedGoogle Scholar
• 30 Koeller D M, Woontner M, Crnic L S, Kleinschmidt-DeMasters B, Stephens J, Hunt E L, Goodmann S I. Biochemical, pathological and behavioral analysis of a mouse model of glutaric aciduria type I.  Hum Mol Gen. 2002;  11 347-357
  PubMedGoogle Scholar
• 31 Kölker S, Ahlemeyer B, Krieglstein J, Hoffmann G F. Maturation-dependent neurotoxicity of 3-hydroxyglutaric and glutaric acids in vitro: A new pathophysiological approach to glutaryl-CoA dehydrogenase deficiency.  Pediatr Res. 2000;  47 495-503
  PubMedGoogle Scholar
• 32 Kölker S, Ahlemeyer B, Hühne R, Krieglstein J, Hoffmann G F. Potentiation of 3-hydroxyglutarate neurotoxicity following induction of astrocytic iNOS in neonatal rat hippocampal cultures.  Eur J Neurosci. 2001;  13 2115-2122
  CrossrefPubMedGoogle Scholar
• 33 Kölker S, Ahlemeyer B, Krieglstein J, Hoffmann G F. Contribution of reactive oxygen species to 3-hydroxyglutarate neurotoxicity in primary neuronal cultures from chick embryo telencephalons.  Pediatr Res. 2001;  50 76-82
  PubMedGoogle Scholar
• 34 Kölker S, Okun J G, Hörster F, Ahlemeyer B, Krieglstein J, Mayatepek E, Hoffmann G F. L-2-Hydroxyglutarazidurie: Evaluation exzitotoxischer Pathomechanismen. Aksu F Aktuelle Neuropädiatrie 2001. Nürnberg; Novartis-Pharma Verlag 2002: 258-261
  Google Scholar
• 35 Kölker S, Okun J G, Ahlemeyer B, Wyse A T, Hörster F, Kohlmüller D. et al . Chronic treatment with glutaric acid induces partial tolerance to excitotoxicity in neuronal cultures from chick embryo telencephalon.  J Neurosci Res. 2002;  68 424-432
  CrossrefPubMedGoogle Scholar
• 36 Kölker S, Pawlak V, Ahlemeyer B, Okun J G, Hörster F, Mayatepek E. et al . NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in D-2-hydroxyglutaric aciduria.  Eur J Neurosci. 2002;  16 21-28
  CrossrefPubMedGoogle Scholar
• 37 Kramer E M, Schardt A, Nave K A. Membrane traffic in myelinating oligodendrocytes.  Microsc Res Tech. 2001;  52 656-671
  CrossrefPubMedGoogle Scholar
• 38 Levine S M, Goldman J E. Spatial and temporal patterns of oligodendrocyte differentiation in rat cerebrum and cerebellum.  J Comp Neurol. 1988;  277 441-455
  PubMedGoogle Scholar
• 39 Li C, Tropak, Gerlai R, Clapoff S, Abramow-Newerly W, Trapp B. et al . Myelination in the absence of myelin-associated glycoprotein.  Nature. 1994;  369 747-750
  CrossrefPubMedGoogle Scholar
• 40 Lima T TF, Begnini J, de Bastiani J, Fialho D B, Jurach A, Pereira Ribeiro M C. et al . Pharmacological evidence for GABAergic and glutamatergic involvement in the convulsant and behavioral effects of glutaric acids.  Brain Res. 1998;  802 55-60
  CrossrefPubMedGoogle Scholar
• 41 Lipton S A, Rosenberg P A. Excitatory amino acids as a final common pathway for neurologic disorders.  New Engl J Med. 1994;  330 613-622
  CrossrefPubMedGoogle Scholar
• 42 Lucas D R, Newhouse J P. The toxic effect of sodium L-glutamate on the inner layers on the retina.  Arch Ophthalmol. 1957;  58 193-201
  PubMedGoogle Scholar
• 43 Matalon R, Michals K, Sebesta D, Deanching M, Gashkoff P, Casanova J. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease.  Am J Med Genet. 1988;  29 463-471
  CrossrefPubMedGoogle Scholar
• 44 Matalon R, Michals K, Kaul R. Canavan disease: from spongy degeneration to molecular analysis.  J Pediatr. 1995;  127 511-517
  CrossrefPubMedGoogle Scholar
• 45 Matalon R, Rady P L, Platt K A, Skinner H B, Quast M J, Campbell G A. et al . Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.  J Gene Med. 2000;  2 165-175
  CrossrefPubMedGoogle Scholar
• 46 Matute C, Sanchez-Gomez M V, Martinez-Millan L, Miledi R. Glutamate-mediated toxicity in optic nerve oligodendrocytes.  Proc Natl Acad Sci. 1997;  94 8830-8835
  CrossrefPubMedGoogle Scholar
• 47 McDonald J W, Althomsons S P, Hyrc K L, Choi D W, Goldberg M P. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity.  Nat Med. 1998;  4 291-297
  CrossrefPubMedGoogle Scholar
• 48 McKinnon R D, Matsui T, Dubois-Dalq M, Aaronson S A. FGF modulates the PDGF-driven pathway of oligodendrocyte development.  Neuron. 1990;  5 603-614
  CrossrefPubMedGoogle Scholar
• 49 Morell P, Quarles R H, Norton W T. Myelin formation, structure, and biochemistry. Siegel GF Basic Neurochemistry: Molecular, Cellular, and Medical Aspects. 5th ed. New York; Raven Press 1994: 117-143
  Google Scholar
• 50 Muntau A C, Röschinger W, Merkenschlager A, van der Knaap M S, Jakobs C, Duran M. et al . Combined D-2- and L-2-hydroxyglutaric aciduria with neonatal onset encephalopathy: a third biochemical variant of 2-hydroxyglutaric aciduria?.  Neuropediatrics. 2000;  31 137-140
  Article in Thieme ConnectPubMedGoogle Scholar
• 51 Neale J H, Bzdega T, Wroblewska B. N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system.  J Neurochem. 2000;  75 443-452
  CrossrefPubMedGoogle Scholar
• 52 Nyhan W L, Shelton D, Jakobs C, Holmes B, Bowe C, Curry C JR. et al . D-2-hydroxyglutaric aciduria.  J Child Neurol. 1995;  10 137-142
  PubMedGoogle Scholar
• 53 Olney J W. Brain lesion, obesity and other disturbances in mice treated with monsodium glutamate.  Science. 1969;  164 719-721
  CrossrefPubMedGoogle Scholar
• 54 Passani L, Elkabes S, Coyle J T. Evidence for the presence of N-acetylaspartylglutamate in cultured oligodendrocytes and LPS activated microglia.  Brain Res. 1998;  25 143-145
  PubMedGoogle Scholar
• 55 Patneau D K, Wright P W, Winters C, Mayer M L, Gallo V. Glial cells of the oligodendrocyte lineage express both kainate- and AMPA-preferring subtypes of glutamate receptor.  Neuron. 1994;  12 357-371
  CrossrefPubMedGoogle Scholar
• 56 Pende M, Holtzclaw L A, Curtis J L, Russell J T, Gallo V. Glutamate regulates intracellular calcium and gene expression in oligodendrocyte progenitors through the activation of DL-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors.  Proc Natl Acad Sci. 1994;  91 3215-3219
  PubMedGoogle Scholar
• 57 Pliss L, Fitz-Gibbon T, Balcar V J, Stasny F. Neurotoxicity of NAAG in vivo is sensitive to NMDA antagonists and mGluR II ligands.  Neuroreport. 2000;  11 3651-3654
  PubMedGoogle Scholar
• 58 Puchalski R B, Louis J C, Brose N, Traynelis S F, Egebjerg J, Kukekov V. et al . Selective RNA editing and subunit assembly of native glutamate receptors.  Neuron. 1994;  13 131-146
  CrossrefPubMedGoogle Scholar
• 59 Quarles R H. Glycoproteins of myelin sheats.  J Mol Neurosci. 1997;  8 1-12
  PubMedGoogle Scholar
• 60 Raff M C, Lillien L E, Richardson W D, Burne J F, Noble M D. Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture.  Nature. 1988;  303 390-396
  PubMedGoogle Scholar
• 61 Toft P B, Geiß-Holtorff R, Rolland M O, Pryds O, Müller-Forell W, Christensen E. et al . Magnetic resonance imaging in juvenile Canavan disease.  Eur J Pediatr. 1993;  152 750-753
  PubMedGoogle Scholar
• 62 Ullrich K, Flott-Rahmel B, Schluff P, Musshoff U, Das A, Lücke T. et al . Glutaric aciduria type I: Pathomechanism of neurodegeneration.  J Inherit Metab Dis. 1999;  22 392-403
  CrossrefPubMedGoogle Scholar
• 63 Valivullah H M, Lancaster J, Sweetman P M, Neale J H. Interactions between N-acetylaspartylglutamate and AMPA, kainate, and NMDA binding sites.  J Neurochem. 1994;  63 1714-1719
  PubMedGoogle Scholar
• 64 Van der Knaap M S, Valk J. Magnetic Resonance of Myelin, Myelination, and Myelin Disorders. 2nd ed. Berlin, Heidelberg, New York; Springer 1995
  Google Scholar
• 65 Van der Knaap M S, Jakobs C, Hoffmann G F, Nyhan W L, Renier W O, Smeitink J AM. et al . D-2-hydroxyglutaric aciduria: biochemical marker or clinical disease entity?.  Ann Neurol. 1999;  45 111-119
  CrossrefPubMedGoogle Scholar
• 66 Yonezawa M, Back S A, Gan X, Rosenberg P A, Volpe J J. Cystine deprivation induces oligodendroglial death: rescue by free radical scavengers and by a diffusible glial factor.  J Neurochem. 1996;  67 566-573
  PubMedGoogle Scholar

Prof. Dr. Georg F. Hoffmann

Department of General Pediatrics
University Children's Hospital Heidelberg

Im Neuenheimer Feld 150

69120 Heidelberg

Germany

Email: Georg_Hoffmann@med.uni-heidelberg.de